Cassidy, Jim and Tabernero, Josep and Twelves, Chris and Brunet, Rene and Butts, Charles and Conroy, Thierry and Debraud, Filippo and Figer, Arie and Grossmann, Johannes and Sawada, Noriaki and Schoffski, Patrick and Sobrero, Alberto and Van Cutsem, Eric and Diaz-Rubio, Eduardo (2004) XELOX (capecitabine plus oxaliplatin): Active first-line therapy for patients with metastatic colorectal cancer. JOURNAL OF CLINICAL ONCOLOGY, 22 (11). pp. 2084-2091. ISSN 0732-183X
Full text not available from this repository. (Request a copy)Abstract
Purpose. Capecitabine has demonstrated high efficacy as first-line treatment for metastatic colorectal cancer (MCRC). Oxaliplatin shows synergy with fluorouracil (FU), with little toxicity overlap. The XELOX regimen (capecitabine plus oxaliplatin), established in a previous dose-finding study, should improve on infused oxaliplatin with FU and leucovorin (FOLFOX) regimens. The present studies further characterize efficacy and safety of the XELOX regimen. Patients and Methods. The antitumor activity of XELOX was investigated in a colon cancer xenograft model. Patients with MCRC received first-line XELOX in 3-week treatment cycles: intravenous oxaliplatin 130 mg/m(2) (day 1) followed by oral capecitabine 1,000 mg/m(2) twice daily (day 1, evening, to day 15, morning). Results. A preclinical study confirmed that capecitabine has supra-additive activity with oxaliplatin. In the clinical study, 53 of 96 patients (55%) achieved an objective response, and 30 (31 %) experienced disease stabilization for greater than or equal to 3 months following treatment. After 24 months' minimum follow-up, median time to disease progression (TTP) and median overall survival were 7.7 and 19.5 months, respectively. XELOX safety was predictable and similar to the FOLFOX4 regimen, except that myelosuppression was uncommon with XELOX (grade 3 or 4 neutropenia, 7%). Most adverse events were mild to moderate, the most common being acute sensory neuropathy (85%). Sixty-day, all-cause mortality was 2%. Conclusion. XELOX is a highly effective first-line treatment for MCRC. Response rates, TTP, and overall survival are similar to those observed with FU/leucovorin/oxaliplatin combinations. XELOX provides a more convenient regimen, likely to be preferred by both patients and healthcare providers. Capecitabine has the potential to replace FU/LV in combination with oxaliplatin for MCRC. (C) 2004 by American Society of Clinical Oncology.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | RANDOMIZED PHASE-III; ORAL CAPECITABINE; FLUOROURACIL-LEUCOVORIN; ADJUVANT THERAPY; COLON-CANCER; TRIAL; 5-FLUOROURACIL; IRINOTECAN; CARCINOMA; INFUSION; |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Innere Medizin I |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 19 Jul 2021 13:39 |
| Last Modified: | 19 Jul 2021 13:39 |
| URI: | https://pred.uni-regensburg.de/id/eprint/37593 |
Actions (login required)
 |
View Item |
